Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 High-Flying Penny Stocks to Buy

Page 1 of 4

In this article, we will look at the 10 High-Flying Penny Stocks to Buy.

​On March 17, Jim Stoeffel and Andrew Palen, Portfolio Managers at Royce Investment Partners, released a research report discussing how micro-caps can stay on top. The report noted that micro-caps have been on an impressive bull run since the April lows in 2025, continuing through February 2026. Notably, the Russell Microcap index has surged 74.5% from April 8, 2025, to February 28, 2026, compared to the 39.7% gains of the Russell 1000 and 39.6% of the S&P 500.

​The portfolio managers noted that the key reason behind sustained market leadership of the micro and small-caps is due to the better relative earnings growth driven by a strong US economy. Moreover, the performance has also been driven by the tougher comparisons for Mag 7 stocks due to inflated earnings expectations on AI capital expenditure. The portfolio managers at Royce Investment expect the performance trend from 2025 to continue in 2026 as well.

​With that, let’s take a look at the 10 High-Flying Penny Stocks to Buy.

​Our Methodology

We used screeners to identify penny stocks (stock price under $5) trading within 0% to 10% of their 52-week highs. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

​10 High-Flying Penny Stocks to Buy

10. Acacia Research Corporation (NASDAQ:ACTG)

Number of Hedge Fund Holders: 10

Acacia Research Corporation (NASDAQ:ACTG) is one of the High-Flying Penny Stocks to Buy. On March 12, Craig-Hallum analyst Anthony Stoss raised the firm’s price target on Acacia Research Corporation (NASDAQ:ACTG) from $5 to $6, while keeping a Buy rating on the stock.

​The analyst noted that the company trades below its diluted book value per share. This presents an attractive entry point and potential undervaluation despite mixed end-market conditions. Moreover, the analyst also pointed out progress at Benchmark Energy, which is a subsidiary of Acacia Research Corporation (NASDAQ:ACTG). Stoss noted that the subsidiary drilled its first Cherokee oil well and is expected to start production in late March 2026. The analyst believes that this can boost overall production by about 10%, with plans for up to three additional wells in the region this year.

​In separate news, Acacia Research Corporation (NASDAQ:ACTG) released its fiscal Q4 2025 results on March 11. The company grew its quarterly revenue by 2.63% year-over-year to $50.13 million and topped expectations by $12.13 million. Moreover, the EPS of $0.03 also topped consensus by $0.17.

​Acacia Research Corporation (NASDAQ:ACTG) acquires and operates businesses in industrial, energy, and technology sectors. Its IP Operations segment invests in intellectual property assets for licensing and enforcement of patented technologies.

​9. Ocugen, Inc. (NASDAQ:OCGN)

Number of Hedge Fund Holders: 14

Ocugen, Inc. (NASDAQ:OCGN) is one of the High-Flying Penny Stocks to Buy. On March 11, Ocugen, Inc. (NASDAQ:OCGN) was initiated with an Outperform rating and a $10 price target at Oppenheimer.

The firm noted that they find the company to be an upcoming leader in gene therapy for blinding ocular disorders. Oppenheimer highlighted the company’s lead asset OCU400, which is currently in Phase 3 trials for retinitis pigmentosa.

​Retinitis pigmentosa is a disease affecting vision. OCU400 targets retinitis pigmentosa with a gene-agnostic approach that could treat multiple genetic mutations, unlike narrower therapies.

The firm noted that a potential approval for OCU400 can offer a near-term opportunity for the company to enter a sizable, underserved rare disease market.

​Moreover, the firm also noted that two other programs for progressively degenerative retinal diseases are in development. Therefore, management is expecting three FDA applications over the next 3 years.

Ocugen, Inc. (NASDAQ:OCGN) is a clinical-stage biotechnology company focused on developing novel gene and cell therapies, biologics, and vaccines to treat retinal diseases and support public health.

Page 1 of 4

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!